150P Cardioimaging in stage III lung cancer patients undergoing chemoRT: Preliminary CARERT results

In our single-center trial, our primary objective is to evaluate acute and delayed cardiac complications using advanced cardiac imaging methods (Cardiac CT and Cardiac MRI) in patients diagnosed with locally advanced non-small cell lung cancer (NSCLC) undergoing radical radiation therapy (RT). We enrolled consecutive stage III NSCLC patients eligible for radical RT. Before treatment initiation and during follow-up, they underwent cardiology assessments, cardiac-MRI, and cardiac-CT. We gathered personal details, comorbidities, treatment information, disease specifics, timing/types of oncological therapies, and cardiological parameters from clinical evaluations, CT, and MRI. This preliminary analysis aims to outline the baseline characteristics of our study's patient cohort. Between November 2022 and October 2023, we enrolled 18 patients: 14 males (77.8%) and 4 females (22.2%), all receiving concurrent or sequential chemo-radiotherapy. 44.4% were former smokers. Interestingly, despite being asymptomatic, cardiac-CT using the Coronary Artery Disease Reporting and Data System (CAD-RADS) revealed no patients with a score of 0. Scores were distributed as follows: 33.3% with a score of 1, 22.2% with a score of 3, and 33.3% with a score of 4. Cardiac-MRI indicated severe cardiac function impairment in four patients. Notably, there was a disparity between clinical cardiac exams and imaging in six out of 14 patients, and two patients (11.1%) underwent percutaneous transluminal coronary angioplasty (PTCA) post-treatment. Our initial findings underscore the clinical significance of cardiac imaging in evaluating stage III lung cancer patients eligible for aggressive treatments. Even in clinically asymptomatic patients, it helps detect cardiac risks, potentially aiding in preventing adverse cardiac conditions.